3 Drugs Stocks On The Rise

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 3 points (0.0%) at 16,495 as of Monday, May 19, 2014, 1:10 PM ET. The NYSE advances/declines ratio sits at 1,891 issues advancing vs. 1,078 declining with 163 unchanged.

The Drugs industry currently sits up 0.7% versus the S&P 500, which is up 0.3%. Top gainers within the industry include Illumina ( ILMN), up 3.6%, and Pfizer ( PFE), up 1.3%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Abbott Laboratories ( ABT) is one of the companies pushing the Drugs industry higher today. As of noon trading, Abbott Laboratories is up $0.54 (1.4%) to $39.60 on average volume. Thus far, 3.1 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.6 million shares. The stock has ranged in price between $39.56-$39.94 after having opened the day at $39.62 as compared to the previous trading day's close of $39.06.

Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $58.9 billion and is part of the health care sector. Shares are up 1.9% year-to-date as of the close of trading on Friday. Currently there are 10 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and relatively poor performance when compared with the S&P 500 during the past year. Get the full Abbott Laboratories Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, AbbVie ( ABBV) is up $0.64 (1.2%) to $53.57 on light volume. Thus far, 1.5 million shares of AbbVie exchanged hands as compared to its average daily volume of 6.1 million shares. The stock has ranged in price between $52.71-$53.71 after having opened the day at $52.90 as compared to the previous trading day's close of $52.93.

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. AbbVie has a market cap of $83.8 billion and is part of the health care sector. Shares are up 0.2% year-to-date as of the close of trading on Friday. Currently there are 5 analysts who rate AbbVie a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk. Get the full AbbVie Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $1.09 (1.4%) to $81.89 on light volume. Thus far, 4.3 million shares of Gilead exchanged hands as compared to its average daily volume of 16.9 million shares. The stock has ranged in price between $80.50-$82.03 after having opened the day at $80.71 as compared to the previous trading day's close of $80.80.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $123.0 billion and is part of the health care sector. Shares are up 7.6% year-to-date as of the close of trading on Friday. Currently there are 18 analysts who rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC